These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9647614)

  • 1. Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
    Brown JM
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):12-4. PubMed ID: 9647614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.
    Denny WA; Wilson WR
    Expert Opin Investig Drugs; 2000 Dec; 9(12):2889-901. PubMed ID: 11093359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tirapazamine: from bench to clinical trials.
    Marcu L; Olver I
    Curr Clin Pharmacol; 2006 Jan; 1(1):71-9. PubMed ID: 18666379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ; Moini M; Giuliano J; Westra WH
    Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
    Brown JM
    Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer.
    Wouters BG; Wang LH; Brown JM
    Ann Oncol; 1999; 10 Suppl 5():S29-33. PubMed ID: 10582136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin.
    Kovacs MS; Hocking DJ; Evans JW; Siim BG; Wouters BG; Brown JM
    Br J Cancer; 1999 Jun; 80(8):1245-51. PubMed ID: 10376978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
    Brown JM
    Mol Med Today; 2000 Apr; 6(4):157-62. PubMed ID: 10740254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia: targeting the tumour.
    Boyle RG; Travers S
    Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tirapazamine: a novel agent targeting hypoxic tumor cells.
    Reddy SB; Williamson SK
    Expert Opin Investig Drugs; 2009 Jan; 18(1):77-87. PubMed ID: 19053884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of cisplatin activity by the bioreductive agent tirapazamine.
    Siemann DW; Hinchman CA
    Radiother Oncol; 1998 May; 47(2):215-20. PubMed ID: 9683372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tirapazamine-cisplatin: the synergy.
    Gatzemeier U; Rodriguez G; Treat J; Miller V; von Roemeling R; Viallet J; Rey A
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):15-7. PubMed ID: 9647615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
    Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.
    Graham MA; Senan S; Robin H; Eckhardt N; Lendrem D; Hincks J; Greenslade D; Rampling R; Kaye SB; von Roemeling R; Workman P
    Cancer Chemother Pharmacol; 1997; 40(1):1-10. PubMed ID: 9137522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice.
    Durand RE; Olive PL
    Radiat Oncol Investig; 1997; 5(5):213-9. PubMed ID: 9372543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts.
    Huxham LA; Kyle AH; Baker JH; McNicol KL; Minchinton AI
    Radiother Oncol; 2006 Feb; 78(2):138-45. PubMed ID: 16455148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro oxygen-dependent survival of 2 human cell lines after radiation combined with tirapazamine (SR-4233) and cisplatin].
    Lartigau E; Stern S; Guichard M
    Cancer Radiother; 2000; 4(3):217-22. PubMed ID: 10897765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bioreductive agents, tirapazamine and mitomycin C, on quiescent cell populations in solid tumors, evaluated by micronucleus assay.
    Masunaga S; Ono K; Hori H; Shibata T; Suzuki M; Kinashi Y; Takagaki M; Akaboshi M
    Jpn J Cancer Res; 1997 Sep; 88(9):907-14. PubMed ID: 9369940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
    Siim BG; van Zijl PL; Brown JM
    Br J Cancer; 1996 Apr; 73(8):952-60. PubMed ID: 8611431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.
    Brown JM
    Cancer Res; 1999 Dec; 59(23):5863-70. PubMed ID: 10606224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.